Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Zdiagnozowany chłoniak małolumfocytowy (SLL) potwierdzony biopsją.
- •Zdiagnozowana przewlekła białaczka limfocytowa (CLL) z określonymi cechami komórek B we krwi.
- •Pacjenci, którzy wcześniej nie byli leczeni z powodu CLL lub SLL.
- •Wszyscy pacjenci zostaną poddani badaniom oceniającym czynniki ryzyka (CLL-IPI).
✗ Disqualifies
- •Nie można wykluczyć chłoniaka z komórek płaszcza.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Mayo Clinic in Arizona
Scottsdale, United States
Mayo Clinic in Florida
Jacksonville, United States
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.